|
Workshop on Immune Reconstitution after Stem Cell TransplantationFriday, April 26th, 2002 Building 10, Masur Auditorium, National Institutes of Health, Bethesda, MD Sponsored by the National Heart, Lung, and Blood Institute and the Department of Transfusion Medicine, NIH The purpose of this workshop is to review the uses of adoptive cellular immune therapy and methods available to evaluate the effects of these therapies. The success of hematopoietic transplants is dependent on the reconstitution of the donor's cellular immune response. Donor cellular immunity must be brisk enough to protect the host from viral infections and to prevent disease relapse, but not so brisk as to cause graft-versus-host disease. In some cases after transplant, the recipient is given either unmanipulated or manipulated donor lymphocytes to treat Epstein Barr virus (EBV) or cytomegalovirus (CMV) infection or induce a graft-versus-leukemia or graft-versus-tumor effect. In addition, some hematologic malignancies and other cancers are being treated with manipulated T cells or with cellular vaccines designed to induce tumor-directed cytotoxicity. While the use of the novel cellular transfusion products is expanding, the monitoring and assessment of these interventions has been inconsistent. This workshop will review current approaches to studying immune reconstitution after stem cell transplantation and identify areas of research in need of research support and development. Agenda Time Topic Speaker 8:00-8:10 a.m. Welcome Liana Harvath Biology of Immune Reconstitution Moderator: H. Heslop 8:10-8:30 a.m. Immunologic basis of the alloresponse John Barrett 8:30-8:50 a.m. B cell immune reconstitution after allogeneic transplants Jan Storek 8:50-9:10 a.m. T cell immune reconstitution after allogeneic transplants Dan Douek 9:10-9:30 a.m. Enhancing immune reconstitution after transplants with cytokines Crystal Mackall 9:30-9:50 a.m. Break 9:50-10:10 a.m. Donor Th2 cells for the prevention of GvHD Dan Fowler 10:10-10:30 a.m. Suicide genes to prevent GvHD Richard O'Reilly 10:30-11:10 a.m. Panel Discussion Enhancing the Immune Response Moderator: J. Barrett 11:10-11:30 a.m. Immune therapy for EBV infections Helen Heslop 11:30-11:50 a.m. Immune therapy for CMV disease H. Einsele 11:50-1:00 p.m. Lunch 1:00-1:20 p.m. Immune therapy for AML Jeff Molldrem 1:20-1:40 p.m. Immune therapy for B cell malignancies John Gribben 1:40-2:00 p.m. Naked DNA modified T cells to treat lymphoma Mike Jensen 2:00-2:20 p.m. NK allorecognition: biology and clinical application in transplants Michael Caliguri 2:20-2:40 p.m. Break 2:40-3:00 p.m. Minor antigens and GvL Stan Riddell 3:00-3:30 p.m. Panel Discussion Regulatory Issues Moderator: E. J. Read 3:30-3:50 p.m. What a cell processing lab can and can't do for immune therapy Adrian Gee Adoptive Immune Therapy, the FDA, and You 3:50-4:10
p.m.
A regulatory approach to donor derived lymphocytes: 4:10-4:20 p.m. A regulatory framework for manipulated cellular products Donald Fink 4:20-4:50 p.m. Panel Discussion To register, e-mail or telephone any of the following: Liana Harvath, Ph.D., NHLBI harvathl@nhlbi.nih.gov, 301-435-0063 Traci Mondoro, Ph.D., NHLBI, mondorot@nhlbi.nih.gov, 301-435-0052 David Stroncek, M.D., CC DTM
dstroncek@mail.cc.nih.gov
|